Anticancer Efficacy of HPPH-PDT Synergies with BCG-Immunotherapy or COX-2 Inhibitor in Treating Bladder Cancer

Area of Science:

• Oncology
• Photodynamic Therapy
• Cancer Immunology

Background:

• 3-(1'-hexyloxy) ethyl-3-devinyl pyropheophorbide-a (HPPH) is a photosensitizer in clinical trials for head and neck and esophageal cancers.
• HPPH-PDT has shown efficacy but can induce COX-2, promoting tumor progression and immune suppression.
• Combination therapies are explored to enhance anticancer effects and overcome resistance.

Purpose of the Study:

• To evaluate the efficacy of HPPH-photodynamic therapy (PDT) on human bladder cancer (BCa) in vitro and in vivo.
• To investigate the role of COX-2/PGE2 pathway in HPPH-PDT response.
• To assess the combined effect of HPPH-PDT with COX-2 inhibition or BCG-immunotherapy.

Main Methods:

• In vitro and in vivo studies using human bladder cancer models in immune-deficient mice.
• Administration of HPPH followed by light activation for PDT.
• Combination treatments involving COX-2 inhibitors or Bacillus Calmette-Guérin (BCG).
• Analysis of tumor uptake, retention, and expression of COX-2, IL-6, VEGF, and PGE2.

Main Results:

• HPPH demonstrated high tumor uptake and retention at 24 hours post-injection.
• HPPH-PDT induced COX-2 and PGE2, associated with immune suppression and tumor progression.
• Combination of HPPH-PDT with COX-2 inhibitors or BCG-immunotherapy significantly improved tumor cure rates.
• Combined therapy reduced expression of COX-2, IL-6, VEGF, and PGE2.

Conclusions:

• HPPH-PDT is effective against human bladder cancer.
• Co-administration of COX-2 inhibitors with HPPH-PDT enhances long-term tumor cure rates.
• The combination strategy effectively modulates key tumor-promoting pathways, offering a promising therapeutic approach.